Treatment emergent adverse events with a frequency of >15%
| Any grade | Grade 3 or 4 | |
|---|---|---|
| Adverse events | Number of patients (%) | |
| Combination phase | ||
| Nausea | 63 (70.8) | 4 (4.5) |
| Fatigue | 54 (60.7) | 9 (10.1) |
| Anorexia | 38 (42.7) | 5 (5.6) |
| Vomiting | 28 (31.5) | 2 (2.2) |
| Constipation | 27 (30.3) | 1 (1.1) |
| Anemia | 26 (29.2) | 10 (11.2) |
| Neutropenia | 26 (29.2) | 15 (16.9) |
| Diarrhea | 25 (28.1) | 1 (1.1) |
| Weight decrease | 18 (20.2) | 2 (2.2) |
| Dysgeusia | 17 (19.1) | 0 |
| Asthenia | 15 (16.9) | 1 (1.1) |
| Peripheral edema | 15 (16.9) | 0 |
| Dizziness | 15 (16.9) | 0 |
| Non–cardiac chest pain | 15 (16.9) | 3 (3.4) |
| Dyspnea | 14 (15.7) | 3 (3.4) |
| Rash | 14 (15.7) | 0 |
| Single-agent phase | ||
| Dyspnea | 13 (23.2) | 3 (5.4) |
| Nausea | 11 (19.6) | 0 |
| Peripheral neuropathy | 10 (17.9) | 0 |
| Fatigue | 10 (17.9) | 3 (5.4) |
| Non–cardiac chest pain | 9 (16.1) | 0 |